Floatz logo

Recombinant Interleukin-12

Recurrent Mantle Cell Lymphoma

National Cancer Institute (NCI)protein_peptidePhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
89/ 100

Competitive context

173 Active assets in the Recurrent Mantle Cell Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Ruijin Hospital
Phase 4BBB
Bendamustine
Czech Lymphoma Study Group
Phase 2BBB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BBB
VINCRISTINE SULFATE
M.D. Anderson Cancer Center
Phase 2BBB
Busulphan
City of Hope Medical Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Recombinant Interleukin-12 is also rated in:

cutaneous melanomaDormant
BB
Indicative ·
68 / 100
View asset →
mycosis fungoidesDormant
BB
Indicative ·
64 / 100
View asset →
primary cutaneous T-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →